MSD has announced plans to start three late-stage studies of Keytruda in patients with metastatic castration-resistant prostate cancer. More: MSD testing Keytruda combos for prostate cancer Source: News
read moreFor years, Johnson & Johnson and the Pfizer-Astellas team have been the only players in their class of prostate-cancer fighters. But Bayer is waiting in the wings, and stellar new safety data could make it a threat. More: With safety
read moreAfter casting off its Indian consumer health franchise, GlaxoSmithKline is selling its Chiron Behring Vaccines unit in India to Bharat Biotech. The transaction will create the world’s largest supplier of rabies vaccines. More: Bharat buys GSK’s Indian vaccine unit to
read moreWhile Big Pharma’s price increases these days are in the single digits—and still triggering Twitter outrage—some small companies aren’t shying away from the old strategy of acquiring drugs and jacking up their prices. More: Egalet's 70% price increase shows the
read moreDr. Reddy’s, which has been struggling to bring a number of its key plants up to FDA standards, has been unable to learn from past mistakes, including at its formulations plant in Bachupally. More: Dr. Reddy's racks up more repeat violations
read moreNICE has recommended use of Alunbrig for treating ALK-positive advanced non-small-cell lung cancer after Xalkori on the NHS in England and Wales. More: Alunbrig recommended by NICE for non-small-cell lung cancer Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals